In a major placebo-controlled pivotal study, Masivet® has demonstrated a high level of efficacy, acting systemically to induce tumour shrinkage and to significantly prolong time to MCT disease progression.1,7
Tumour response rates from the pivotal study, together with data from three independent clinical investigations in dogs with inoperable Grade 2 and Grade 3 MCTs, are presented below1,2,3,4,5
In the pivotal study, 50% of dogs receiving Masivet® demonstrated a complete response or significant partial response during the first 6 months of therapy (p = 0.02 vs. placebo).1
